• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    6/29/23 9:12:44 AM ET
    $BDTX
    $BTAI
    $CRMD
    $DMTK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDTX alert in real time by email

    Gainers

    • Sigilon Therapeutics (NASDAQ:SGTX) stock increased by 657.8% to $29.78 during Thursday's pre-market session. The company's market cap stands at $74.5 million.
    • RenovoRx (NASDAQ:RNXT) shares increased by 29.91% to $2.91. The market value of their outstanding shares is at $29.4 million.
    • Kintara Therapeutics (NASDAQ:KTRA) stock rose 18.39% to $3.54. The market value of their outstanding shares is at $5.9 million.
    • Immunome (NASDAQ:IMNM) shares moved upwards by 18.1% to $6.98. The company's market cap stands at $85.2 million.
    • Plus Therapeutics (NASDAQ:PSTV) shares rose 15.0% to $2.99. The market value of their outstanding shares is at $7.4 million.
    • DermTech (NASDAQ:DMTK) stock moved upwards by 12.49% to $2.52. The company's market cap stands at $78.3 million.

    Losers

    • BioXcel Therapeutics (NASDAQ:BTAI) shares declined by 56.9% to $7.61 during Thursday's pre-market session. The company's market cap stands at $221.9 million.
    • Cormedix (NASDAQ:CRMD) stock declined by 24.07% to $3.85. The market value of their outstanding shares is at $174.7 million.
    • Surgalign Holdings (NASDAQ:SRGA) stock fell 15.53% to $0.25. The company's market cap stands at $2.3 million.
    • Black Diamond Therapeutic (NASDAQ:BDTX) stock fell 12.57% to $5.01. The market value of their outstanding shares is at $182.9 million.
    • Minerva Neurosciences (NASDAQ:NERV) stock fell 10.11% to $9.16. The company's market cap stands at $51.0 million.
    • Dermata Therapeutics (NASDAQ:DRMA) shares decreased by 10.0% to $1.53. The market value of their outstanding shares is at $4.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BDTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDTX
    $BTAI
    $CRMD
    $DMTK

    CompanyDatePrice TargetRatingAnalyst
    Immunome Inc.
    $IMNM
    2/12/2026$40.00Buy
    H.C. Wainwright
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Immunome Inc.
    $IMNM
    12/1/2025$36.00Buy
    Truist
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    CorMedix Inc.
    $CRMD
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    Immunome Inc.
    $IMNM
    9/22/2025$26.00Buy
    Goldman
    More analyst ratings

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Zelnick Kaufman Beth was granted 36,006 shares, increasing direct ownership by 15% to 269,108 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:06 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Todisco Joseph was granted 77,156 shares, increasing direct ownership by 11% to 774,749 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:03 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Hurlburt Elizabeth was granted 36,006 shares, increasing direct ownership by 15% to 278,539 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    2/6/26 9:30:04 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    SEC Filings

    View All

    Dermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dermata Therapeutics, Inc. (0001853816) (Filer)

    2/25/26 4:05:32 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13D/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/23/26 7:56:24 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/18/26 4:49:52 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting

    MOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting has been accepted. The meeting will be held April 11-15, 2026, in Toronto, Ontario. The abstract, titled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer," was submitted by a multidisciplinary team of cancer experts, i

    2/26/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery (CED) used in the administration of REYOBIQ for recurrent glioblastoma (rGBM) and pediatric brain cancer (PBC).   "The approved Category III CPT code for convection-enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer – the most

    2/25/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Immunome to Present at Upcoming Investor Conferences

    Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date/Time: March 3, 2026, at 9:50 a.m. ET Leerink Partners Global Healthcare Conference Presentation Date/Time: March 10, 2026, at 3 p.m. ET Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company's website at www.immunome.com. Replay webcasts will be available for approximately 30 days following the live presentations.

    2/23/26 8:00:00 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $169 worth of shares (205 units at $0.83), increasing direct ownership by 0.03% to 778,665 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/2/26 5:00:20 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Immunome with a new price target

    H.C. Wainwright initiated coverage of Immunome with a rating of Buy and set a new price target of $40.00

    2/12/26 7:24:43 AM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lake Street initiated coverage on Plus Therapeutics with a new price target

    Lake Street initiated coverage of Plus Therapeutics with a rating of Buy and set a new price target of $2.00

    2/3/26 8:52:26 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Therapeutics Announces Leadership and Board Updates

    BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director. "Under t

    1/8/26 8:05:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery (CED) used in the administration of REYOBIQ for recurrent glioblastoma (rGBM) and pediatric brain cancer (PBC).   "The approved Category III CPT code for convection-enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer – the most

    2/25/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization

    HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. "Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness," said Dr. Marc H. Hedrick, President & Chief Executive of Plus Therapeutics. "Our recently completed upsized $15 million offering will fuel faster progress in these core areas of the business and extend our cash runway through 2027." Overview of anticipated

    1/22/26 7:45:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

    HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Webcast and Conference Call Date/Time:Thursday, January 22, 2026 @ 9:00 AM ETWebcast:https://event.choruscall.com/mediaframe/webcast.html?webcastid=x5QZCyIkParticipant Dial-in:1-888-349-0106   Please di

    1/21/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $BDTX
    $BTAI
    $CRMD
    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Immunome Inc.

    SC 13G/A - Immunome Inc. (0001472012) (Subject)

    11/14/24 9:00:58 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

    SC 13G/A - CorMedix Inc. (0001410098) (Subject)

    11/14/24 4:34:05 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care